Pharmaceutical Firm Darnitsa

Pharmaceutical Firm Darnitsa is rated 3 out of 5 in the category pharmaceuticals. Read and write reviews about Pharmaceutical Firm Darnitsa. DARNITSA develops, manufactures and markets a broad portfolio, which includes 280 generic products in the Rx and OTC segments. The company is the leader in focused therapeutic areas: cardiology, neurology, pain management, with a strategic presence in the largest and rapidly growing ATC classes in Ukraine: cardiovascular, CNS, alimentary, anti-infectives and musculoskeletal. DARNITSA operates its own modern, fully GMP-certified production plant with an annual capacity of 670 million packages in various dosage: solid dosages including tablets and granules, solutions for injections in ampoules, LVP solutions based on BFS technology, sterile vials of antibiotics, tubes of soft medicines, sterile and non-sterile drops, semi-solids, parenteral cephalosporins, infusion solutions, etc. A line of self-developed products and licensed products is under development in the modern R&D laboratory. Our team has extensive experience in development of value-added generics, efficientmanufacturing processes and operations. We export products to 16 countries around the world having more than 400 registration abroad. The Company is actively exploring opportunities for expansion through M&A on international markets as well it is open to licensing agreements, joint R&D, dossier/portfolio acquisitions,including potential partnerships in financing such agreements.